Chairman Otto Buttula's "partial underwriting" of only 3.6 million shares @ $361,658 shows that not even he thinks it's worth putting too much on the line for this company. Yet he was happy to cling on to his position on the Board, with the only new ideas they've had recently seeming to be the failed capital raise and the uninspiring establishment of an "internationally renowned clinical advisory board". The future doesn't look good for RHY, sadly.
Ann: Close of Rights Issue, page-5
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
